Who Qualifies for GLP-1 Weight Loss Medication?
Qualifying for a GLP-1 or related weight-management medication is not the same as receiving a prescription, having insurance coverage, or knowing that a product is safe for one person. FDA indication, body-mass index (BMI), weight-related conditions, medication and medical history, contraindications, prior treatment, product availability, ability to follow long-term care, and patient preference all matter. Semaglutide and tirzepatide products also have different approved uses, so brand and indication cannot be treated as interchangeable.
Seek urgent care for severe abdominal pain, repeated vomiting, dehydration, chest pain, fainting, or symptoms that feel unsafe.
Board-certified gastroenterologist and internist · MWI contributor for metabolic health and colorectal screening education
Last reviewed July 23, 2026
- For chronic weight management, FDA-approved products are generally considered for adults with obesity or with overweight plus at least one weight-related condition, within each product's label.
- BMI is a screening measure, not a complete health assessment or a guarantee of candidacy.
- Personal or family medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2 are boxed-warning contraindication contexts for Wegovy and Zepbound.
- Pregnancy, pancreatitis or gallbladder history, severe gastrointestinal symptoms, kidney risk, diabetes medicines, surgery plans, and other factors require product-specific review.
- Insurance and supply decisions are separate from medical appropriateness. Do not assume qualification means coverage or an immediate prescription.
Start with the product's approved indication
GLP-1 is a medication class, not one interchangeable prescription. Wegovy contains semaglutide and Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Other semaglutide and tirzepatide brands have diabetes indications and should not be described as identical weight-management products.
The FDA label defines who the product is approved to treat, important contraindications, warnings, administration, and monitoring. A clinician may decide that a person meets an indication but still has a safety, interaction, access, or follow-up reason to choose a different plan.
BMI opens a conversation; it does not finish the evaluation
NIDDK explains that prescription weight-management medicines may be considered for adults with a BMI of 30 or greater, or a BMI of 27 or greater with weight-related health problems, in addition to lifestyle treatment. The exact indication and age group must be confirmed on the current product label.
BMI does not directly measure body composition, fat distribution, fitness, nutrition, or individual risk. The visit should also consider waist pattern, blood pressure, glucose, cholesterol, sleep apnea risk, liver and kidney health, mobility, prior weight trajectory, medicines, and how weight affects daily function.
A candidacy decision map
| Decision area | What the clinician verifies | Why it matters |
|---|---|---|
| Indication | BMI, age, weight-related conditions, and exact FDA-approved product use | A class name or social-media claim does not establish on-label candidacy |
| Medical safety | Thyroid-cancer context, pregnancy, pancreas and gallbladder history, gastrointestinal disease, kidney risk, allergy | Contraindications and warnings differ in importance by the individual's history |
| Medication safety | Diabetes medicines, insulin or sulfonylureas, medicines affected by delayed stomach emptying, weight-loss products | Interactions and low-blood-sugar risk may require coordinated management |
| Treatment readiness | Nutrition, activity, side-effect plan, follow-up access, injection training, long-term expectations | Medication works within ongoing care, not as a one-time transaction |
| Access | Coverage criteria, prior authorization, pharmacy supply, approved source, total cost | Medical candidacy does not guarantee insurance approval or availability |
Contraindications and warnings need the exact label
Current Wegovy and Zepbound labels carry a boxed warning related to thyroid C-cell tumors observed in rodents and contraindicate use in people with a personal or family history of medullary thyroid carcinoma or MEN 2. The relevance of other thyroid conditions should be discussed rather than guessed.
The clinician should also review pregnancy or pregnancy plans, prior serious allergic reaction, pancreatitis and gallbladder history, severe or persistent gastrointestinal symptoms, kidney problems or dehydration risk, diabetes complications, and medicines that could interact. This is not an exhaustive list; the current label and patient's history control the decision.
Baseline evaluation should connect weight to health
A useful evaluation reviews weight history, prior approaches, nutrition, activity, sleep, alcohol, medicines that promote weight gain, mental health and eating-disorder history, blood pressure, and obesity-related conditions. Directed labs may include glucose or A1C, lipids, kidney and liver context, and other tests suggested by history.
The visit should define success beyond a scale number: blood-pressure improvement, diabetes prevention or control, sleep and mobility, liver risk, sexual health, medication reduction, and sustainable routines may matter. No outcome is guaranteed.
Coverage and availability are separate gates
A clinician can consider a product medically appropriate while an insurance plan denies it, requires documentation, or covers a different drug. Employers and plans use different obesity benefits, diagnosis rules, step requirements, and prior-authorization processes. Coverage can change.
Verify the exact product, indication, pharmacy, monthly cost, deductible, authorization duration, and renewal requirements. Manufacturer offers have eligibility rules and should not be presented as guaranteed. Do not buy a product from an unverified source because coverage is difficult.
Approved, compounded, and counterfeit products are not equivalent
FDA-approved medicines undergo review for quality, safety, and effectiveness and use an approved label. FDA has warned about unapproved and compounded GLP-1 products, including dosing errors, fraudulent products, and salt forms that are not the same active ingredient as an approved product.
Compounding can have a lawful role under specific conditions, but it does not make a product FDA approved. Ask the prescriber and pharmacy exactly what is being supplied, why, how it is measured, and what regulatory and quality safeguards apply.
Long-term follow-up is part of candidacy
A candidate needs a plan for side effects, hydration, nutrition, protein and muscle preservation, activity, medication interactions, laboratory follow-up, and what happens if treatment is interrupted or stopped. Weight regain can occur after discontinuation, so maintenance planning belongs before treatment.
The prescriber should name who manages diabetes medicines, procedure or surgery instructions, pregnancy planning, severe symptoms, and authorization renewals. A prescription without reachable follow-up is not a complete program.
Questions to bring to a GLP-1 evaluation
- Which exact FDA-approved product and indication are we discussing?
- Do my BMI and weight-related conditions fit that label?
- What history, medicine, or warning could make it inappropriate?
- Which baseline measurements or labs would change the decision?
- How will side effects, nutrition, muscle, blood pressure, and metabolic health be followed?
- Who coordinates diabetes medicines and surgery or procedure planning?
- What does insurance require, and what is the verified total cost?
- What is the plan if the medicine is unavailable, not tolerated, or stopped?
Move from education into the right clinical conversation.
Frequently asked questions
What BMI qualifies for GLP-1 weight loss medication?
For chronic weight management, FDA-approved products are generally considered at BMI 30 or greater, or BMI 27 or greater with a weight-related condition, within the exact label and clinical evaluation.
Does qualifying mean insurance will cover it?
No. Medical candidacy and insurance coverage are separate. Plans may exclude obesity medicines or require diagnoses, prior authorization, step rules, and renewal evidence.
Can someone without diabetes qualify?
Some FDA-approved products have chronic weight-management indications that do not require diabetes. The exact product label, BMI, conditions, and safety review still apply.
Who should not take Wegovy or Zepbound?
Both labels include contraindications involving personal or family medullary thyroid carcinoma or MEN 2 and product-specific warnings. A prescriber must review the full history and current label.
Do I need blood tests before a GLP-1 medicine?
Testing is individualized. Glucose, kidney, liver, lipid, pregnancy, or other evaluation may be useful depending on history, medicines, and the product considered.
Are compounded GLP-1 medicines the same as FDA-approved products?
No. Compounded drugs are not FDA approved. FDA has warned about dosing errors, fraudulent products, and products using ingredients that differ from approved drugs.
Is a GLP-1 medication a short-term treatment?
Obesity is chronic, and weight regain can occur after treatment stops. Candidacy should include a long-term follow-up and maintenance discussion.
This page is educational and does not provide medical advice, diagnosis, or treatment. A clinician must evaluate your individual situation.